Simon Sturge leaves Boehringer Ingelheim to head Merck's biosimilars unit, as well as the European Medicines Agency, Shire and EFPIA in this week's People on the Move column.
Boehringer Ingelheim’s head of biopharmaceuticals Simon Sturge will join Merck KGaA as head of its biosimilars unit.
Merck’s biosimilars unit was set up in early 2012 to develop therapies for oncology and inflammatory disorders through in-house R&D and collaborations with other biosimilars developers, including Dr Reddy’s Laboratories.
The unit is located in Merck’s biologics manufacturing facilities in Aubonne and Corsier sur Vevey, Switzerland.
“Merck has all the capabilities to compete in biosimilars and we expect significant growth of this market by the end of the decade,” said Stefan Oschmann, head of pharmaceuticals at Merck. “Simon Sturge is ideally suited to develop our biosimilars unit and to be among the important players in this field.”
Before joining Boehringer Ingelheim, Sturge, now 54, was CEO of Dutch biotech OctoPlus and CEO of Vernalis.
For an interactive timeline of Merck KGaA and Merck & Co. and their 100-year split, click here .
Copyright - Unless otherwise stated all contents of this web site are © 2015 - William Reed Business Media SAS - All Rights Reserved - Full details for the use of materials on this site can be found in the Terms & Conditions
Plus more jobs news from the pharmaceutical world, including senior changes at PhRMA.